Abstract
Herein, we present an overview on the current status of the characterization techniques and methodologies used to study the physicochemical descriptors that influence the final clinical performance of a given nanomedicine. The described techniques were selected based on their suitability to operate under relevant “native” conditions that mimic the physiological environment. Special emphasis is placed on those techniques that hold a greater potential to unravel dynamic, structural, and compositional features of soft organic nanomedicines relevant to the ability to bypass biological barriers, and hence allow for the rational design of drug delivery platforms with improved biological output.
Keywords: Nanomedicines, drug delivery systems, biological barriers, characterization techniques, polymer therapeutics.
Current Pharmaceutical Design
Title:Relevant Physicochemical Descriptors of “Soft Nanomedicines” to Bypass Biological Barriers
Volume: 22 Issue: 9
Author(s): Amaya Nino-Pariente, Vicent J. Nebot and Maria J. Vicent
Affiliation:
Keywords: Nanomedicines, drug delivery systems, biological barriers, characterization techniques, polymer therapeutics.
Abstract: Herein, we present an overview on the current status of the characterization techniques and methodologies used to study the physicochemical descriptors that influence the final clinical performance of a given nanomedicine. The described techniques were selected based on their suitability to operate under relevant “native” conditions that mimic the physiological environment. Special emphasis is placed on those techniques that hold a greater potential to unravel dynamic, structural, and compositional features of soft organic nanomedicines relevant to the ability to bypass biological barriers, and hence allow for the rational design of drug delivery platforms with improved biological output.
Export Options
About this article
Cite this article as:
Nino-Pariente Amaya, Nebot J. Vicent and Vicent J. Maria, Relevant Physicochemical Descriptors of “Soft Nanomedicines” to Bypass Biological Barriers, Current Pharmaceutical Design 2016; 22 (9) . https://dx.doi.org/10.2174/1381612822666151216152143
DOI https://dx.doi.org/10.2174/1381612822666151216152143 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multiple Protective Functions of Sigma1 Receptor
Current Protein & Peptide Science Death Receptors as Targets of Cancer Therapeutics
Current Cancer Drug Targets Molecular Probes for Malignant Melanoma Imaging
Current Pharmaceutical Biotechnology Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews Therapeutic Targeting of G-Protein Coupled Receptor-Mediated Epidermal Growth Factor Receptor Transactivation in Human Glioma Brain Tumors
Mini-Reviews in Medicinal Chemistry Natural Products Derived from Traditional Chinese Medicine as Novel Inhibitors of the Epidermal Growth Factor Receptor
Combinatorial Chemistry & High Throughput Screening Optimising the Azeotropic Drying of 18F-Fluorine Wayto Improve the 18F-Fluorocholine Radiochemical Yield
Current Radiopharmaceuticals The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue
CNS & Neurological Disorders - Drug Targets High Throughput Study for Molecular Mechanism of Metformin Pre-Diabetic Protection <i>via</i> Microarray Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets NCRNA Combined Therapy as Future Treatment Option for Cancer
Current Pharmaceutical Design Cancer and Cyclooxygenase-2 (COX-2) Inhibition
Current Pharmaceutical Design Autoantibody Profiles as Biomarkers for Response to Therapy and Early Detection of Cancer
Current Cancer Therapy Reviews Update on Screening in Prostate Cancer Based on Recent Clinical Trials
Reviews on Recent Clinical Trials Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
Current Drug Targets Physiology and Therapeutics of Vascular Endothelial Growth Factor in Tumor Immunosuppression
Current Molecular Medicine Adjuvant Hormonal Therapy in Women with Early-stage Breast Cancer
Medicinal Chemistry Meet the Editorial Board:
Current Medicinal Chemistry Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Selenium and Cardiovascular Surgery: An Overview
Current Drug Safety Cell-Specific Induction of Apoptosis by Rationally Designed Bivalent Aptamer-siRNA Transcripts Silencing Eukaryotic Elongation Factor 2
Current Cancer Drug Targets